Awakn Life Sciences Corp.
AWKN
CNSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 42.19% | 80.90% | 65.78% | 59.99% | 60.92% |
| Total Depreciation and Amortization | -28.26% | 25.93% | 34.62% | 45.83% | 70.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -72.97% | 101.10% | -94.88% | -1.72% | -88.24% |
| Change in Net Operating Assets | -117.56% | -34.01% | -98.32% | 1,390.02% | -242.88% |
| Cash from Operations | 9.66% | 100.08% | 33.57% | 95.59% | 8.72% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 6,328.57% | 100.00% |
| Cash from Investing | -- | -- | -- | -100.00% | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -48.70% | -29.92% | -81.90% | -- | -30.48% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 140.12% | -100.00% |
| Cash from Financing | -48.98% | -23.75% | -79.85% | -101.96% | -58.15% |
| Foreign Exchange rate Adjustments | -127.93% | -100.77% | 106.18% | 11.90% | 103.43% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -264.67% | 117.91% | -77.48% | 74.72% | -81.19% |